Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
 

Blood Cancer Clinical Trials

A listing of Blood Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (747) clinical trials

Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib. Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin ...

Phase

Safety and Tolerability Study in Solid Tumors

This is an open-label, multicenter, sequential dose-escalation, and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy. The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part. Part A ...

Phase

S1216 Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

Phase

A Study to Investigate the Safety and Efficacy of an Anti-IFN mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis

The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, ...

Phase

A Two-part Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies

Phase

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

This is a prospective, multi-regional, observational cohort study with up to 3 years of follow up per patient. During the entire observational period (from the first patient first visit to the last patient last visit), vital status will be collected every 6 months on all patients, including those who complete ...

Phase N/A

A Phase 1 Multiple Ascending Dose Study of DS-3032b an Oral Murine Double Minute 2 (MDM2) Inhibitor in Subjects With Advanced Solid Tumors or Lymphomas

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic (PK)/ pharmacodynamic (PD) properties in subjects with advanced solid tumors or lymphomas. Approximately 5 US sites are planned for ...

Phase

Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Relapsed and/or Refractory Mantle Cell Lymphoma (MCL): Study Drug Administration: If participant is found to be eligible for this study, participant will begin the first cycle of treatment with ibrutinib and rituximab. Each cycle is 28 days. Ibrutinib Administration: Every day participant will take 4 ibrutinib capsules with 1 cup ...

Phase

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant,

Phase

AC220 With 5-Aza or Low Dose Cytarabine

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to receive quizartinib with azacitidine or cytarabine. Your doctor will decide which drugs you will receive. You will be assigned to a study phase based on when you join this study. ...

Phase